NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) has been awarded first place in the Healthcare category at the BOLD Awards VII, held March 27, 2026, in Barcelona. The recognition underscores the company's leadership in developing exosome-based therapies for central nervous system (CNS) injuries, particularly its lead product ExoPTEN, which has shown strong preclinical data for treating acute spinal cord and optic nerve injuries. The BOLD Awards, judged by a panel of global industry leaders, highlight innovative companies driving significant impact in their sectors.
In a corporate update, NurExone also announced plans to engage Investor Brand Network (IBN) to support its investor awareness efforts, subject to approval from the TSX Venture Exchange. The agreement, set to begin April 1, 2026, involves a monthly fee of $6,500 for a one-year term, with IBN distributing news and updates across more than 5,000 outlets. This initiative aims to strengthen market visibility and build long-term shareholder value as NurExone advances its clinical roadmap.
The award and investor outreach come at a pivotal time for NurExone, which is focused on regenerative exosome-based therapies for CNS injuries. ExoPTEN, the company's flagship product, has received Orphan Drug Designation, facilitating the path toward clinical trials in the United States and Europe. The therapy addresses significant unmet medical needs, as current treatments for spinal cord and optic nerve injuries are limited. By leveraging exosomes as a targeted delivery system, NurExone aims to provide minimally invasive solutions that could improve patient outcomes.
Commercially, NurExone is expected to offer its expertise in quality exosome production and targeted delivery systems to other companies, potentially expanding its reach beyond CNS indications. The company has established Exo-Top, a U.S. subsidiary, to anchor its North American activities and growth strategy. The BOLD Awards recognition and the planned engagement with IBN are likely to enhance NurExone's profile among investors and stakeholders, supporting its mission to bring innovative therapies to market.
For more information on NurExone, visit the company's website at https://nurexone.com/. The full press release can be accessed at https://ibn.fm/cWtqT.
